Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.04
+0.39 (3.35%)
Aug 25, 2026, 4:00 PM EDT - Market closed

Zevra Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
58.2683.23-105.51-46.05-26.77-8.56
Depreciation & Amortization
1.494.056.391.010.940.26
Other Amortization
-----0.15
Loss (Gain) From Sale of Assets
-43.25-148.260.220.160.010.08
Asset Writedown & Restructuring Costs
-58.71--17.66-
Loss (Gain) From Sale of Investments
-3.09-3.28-0.87-0.610.58-
Stock-Based Compensation
13.1312.7115.386.184.522.74
Other Operating Activities
10.5817.7521.92-0.1-15.2516.13
Change in Accounts Receivable
-3.86-11.986.87-9.08-6.771.05
Change in Inventory
-1.04-1.31-8.870.210.15-
Change in Accounts Payable
-2.53-15.59-3.611.133.13-1.11
Change in Other Net Operating Assets
3.712.36-1.593.633.09-0.3
Operating Cash Flow
33.4-1.6-69.67-33.54-18.7210.44
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.78-0.84--0.3-0.09-0.1
Sale of Property, Plant & Equipment
49.380.45----
Cash Acquisitions
----30.4-14.09-
Investment in Securities
58.11-131.49-16.1613.31-22.54-15.42
Other Investing Activities
-150-6---
Investing Cash Flow
106.7218.13-22.16-17.39-36.72-15.52

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--60.0743.6914.07-
Long-Term Debt Repaid
--0.37-43.13-18.1-1.32-38.1
Net Debt Issued (Repaid)
-60.09-0.3716.9425.5912.75-38.1
Issuance of Common Stock
19.4312.4467.266.320.32158.24
Repurchase of Common Stock
-1.49---3.45-4.72-2.81
Other Financing Activities
---2.09---4.22
Financing Cash Flow
-42.1412.0682.1128.468.35113.11

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.370.030.450.040.2-
Net Cash Flow
97.6128.62-9.26-22.42-46.88108.02

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
32.62-2.43-69.67-33.83-18.8110.34
Free Cash Flow Growth
------
Free Cash Flow Margin
23.98%-2.28%-295.04%-123.20%-185.12%36.08%
Free Cash Flow Per Share
0.55-0.04-1.51-0.95-0.550.35
Levered Free Cash Flow
48.38-1.96-36.36-10.32-106.31
Unlevered Free Cash Flow
51.953.03-31.77-9.39-9.796.39

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
4.075.335.260.460.320.22
Change in Working Capital
-3.72-26.51-7.195.88-0.41-0.36
SEC Filings: 10-K · 10-Q